Evidence map›Paper›PMID 34285701›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2021

The Effects of

Rasool Soltani, Syed Mustafa Ghanadian, Bijan Iraj, Alireza Homayouni, Tanin Shahmiveh Esfahani, Mojtaba Akbari

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rasool SoltaniDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0001-9301-4732
Syed Mustafa GhanadianIsfahan Pharmaceutical Research Center, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0001-6446-4734
Bijan IrajIsfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0003-0561-408X
Alireza HomayouniDepartment of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0002-5308-2092
Tanin Shahmiveh EsfahaniStudents Research Committee, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0002-0515-8136
Mojtaba AkbariDepartment of Epidemiology and Statistics, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0002-5777-9612
Isfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsIn a randomized controlled clinical trial, patients with T2DM who met the inclusion criteria were randomly divided into two groups of drug (

resultsDuring the study, 30 and 35 patients in the drug and control groups, respectively, completed the study. Although no significant changes occurred in any parameter within each group, postintervention FBS (117.5 [107-128.8] versus 134 [120-142],

conclusionConsumption of

Identifiers

PMID34285701
PMCPMC8275404
OpenAlexW3178214551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.